Millennium Physician Group — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$6,097	1
2024	Research	$15,829	3
2022	Research	$682	1
2021	Research	$1,000	1
2020	Research	$9,644	3
2019	Research	$21,861	3

Breakdown

Who paid Research payments · program years 2019–2025

Eli Lilly and Company $43,634 10 payments
Becton, Dickinson and Company $11,480 2 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (Lucent 1) $27,159 6 payments
QuickSilver $11,480 2 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $10,446 2 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (Lucent 2) $6,028 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.